Release study of selected terpenes from nanostructured lipid carriers

Colloids and Surfaces A: Physicochemical and Engineering Aspects

Volumn 510, Issue , 2016, Pages 87-92

  Lasoń, Elwira ^a   Sikora, Elżbieta ^a   Ogonowski, Jan ^a   Tabaszewska, Małgorzata ^b   Skoczylas, Łukasz ^b  

^a CRACOW UNIVERSITY OF TECHNOLOGY   (Poland)

^b UNIVERSITY OF AGRICULTURE IN KRAKOW   (Poland)

Author keywords

Controlled release; Forskolin; Geranic acid; Nanostructured lipid carriers; Terpenes; Ursolic acid

Indexed keywords

CARBOXYLIC ACIDS; DIALYSIS MEMBRANES; HOMOGENIZATION METHOD; PARTICLE SIZE;

CONTROLLED RELEASE; FORSKOLIN; GERANIC ACID; NANOSTRUCTURED LIPID CARRIERS; URSOLIC ACID;

TERPENES;

ACID; ALCOHOL; CELLULOSE; DECANOIC ACID; FORSKOLIN; GERANIC ACID; LIPID; NANOCARRIER; NANOSTRUCTURED LIPID CARRIER; OCTANOIC ACID; PROPOLIS; TERPENE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; URSOLIC ACID;

ARTICLE; CHEMICAL STRUCTURE; CONTROLLED DRUG RELEASE; DIALYSIS MEMBRANE; DISPERSITY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; IN VITRO STUDY; LIQUID; MOLECULAR STABILITY; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; SHEAR RATE; ULTRASOUND; VISCOSITY; ZETA POTENTIAL;

EID: 84978382731     PISSN: 09277757     EISSN: 18734359     Source Type: Journal    
DOI: 10.1016/j.colsurfa.2016.06.021     Document Type: Article

References (39)

1. [1] Bution, M., Molina, G., Abrahão, M., Pastore, G., Genetic and metabolic engineering of microorganisms for the development of new flavor compounds from terpenic substrates. Crit. Rev. Biotechnol. 35 (2015), 313–325.
2. [2] Charoenputtakun, P., Pamornpathomkul, B., Opanasopit, P., Rojanarata, T., Ngawhirunpat, T., Terpene composited lipid nanoparticles for enhanced dermal delivery of all-trans-retinoic acids. Biol. Pharm. Bull. 37 (2014), 1139–1148.
3. [3] Reddy, L., Couvreur, P., Squalene: a natural triterpene for use in disease management and therapy. Adv. Drug Deliv. Rev. 61 (2009), 1412–1426.
4. [4] Cal, K., Janicki, S., Sznitowska, M., In vitro studies on penetration of terpenes from matrix-type transdermal systems through human skin. Int. J. Pharm. 224 (2001), 81–88.
5. [5] Mi, J., Becher, D., Lubuta, P., Dany, S., Tusch, K., Schewe, H., Buchhaupt, M., Schrader, J., De novo production of the monoterpenoid geranic acid by metabolically engineered Pseudomonas putida. Microb. Cell Fact., 13, 2014, 170.
6. [6] Yang, T., Stoopen, G., Yalpani, N., Vervoort, J., de Vos, R., Voster, A., Verstappen, F., Bouwmeester, H., Jongsma, M., Metabolic engineering of geranic acid in maize to achieve fungal resistance is compromised by novel glycosylation patterns. Metab. Eng. 13 (2011), 414–425.
7. [7] Masuda, T., Odaka, Y., Ogawa, N., Nakamoto, K., Kuninaga, H., Identification of geranic acid, a tyrosinase inhibitor in lemongrass (Cymbopogon citratus). J. Agric. Food Chem. 56 (2008), 597–601.
8. [8] Wang, N., Hebert, D., Tyrosinase maturation through the mammalian secretory pathway: bringing color to life. Pigment Cell Res. 19 (2006), 3–18.
9. [9] Choi, S., Inhibitory effects of geranic acid derivatives on melanin biosynthesis. J. Cosmet. Sci. 63 (2012), 351–358.
10. [10] Patel, M., Forskolin a successful therapeutic phytomolecule. East Cent. Afr. J. Pharm. Sci. 13 (2010), 25–32.
11. [11] Fradkin, J., Cook, G., Kilhoffer, M., Wolff, J., Forskolin stimulation of thyroid adenylate cyclase and cyclic 3′,5′-adenosine monophosphate accumulation. Endocrinology 111 (1982), 849–856.
12. [12] Ammon, H., Müller, A., Forskolin: from an ayurvedic remedy to a modern agent. Planta Med. 51 (1985), 473–477.
13. [13] Caprioli, J., Sears, M., Combined effect of forskolin and acetazolamide on IOP and aqueous flow in rabbit eye. Exp. Eye Res. 39 (1984), 47–50.
14. [14] Lee, P., Podos, S., Serle, J., Camras, C., Severin, C., Intraocular pressure effects of multiple doses of drugs applied to glaucomatous monkey eyes. Arch. Ophthalmol. 105 (1987), 249–252.
15. [15] Matsumoto, S., Yamashita, T., Araie, M., Kametani, S., Hosokawa, T., Takase, M., The ocular penetration of topical forskolin and its effects on intraocular pressure, aqueous flow rate and cyclic AMP level in the rabbit eye. Jpn. J. Ophthalmol. 34 (1990), 428–435.
16. [16] Shivaprasad, H., Pandit, S., Bhanumathy, M., Manohar, D., Jain, V., Afsar, S., Su, X., Ethnopharmacological and phytomedical knowledge of Coleus forskohlii: an approach towards its safety and therapeutic value. Orient. Pharm. Exp. Med. 14 (2014), 301–312.
17. [17] Spry, M., Vanover, J., Scott, T., Abona-Ama, O., Wakamatsu, K., Ito, S., D'Orazio, J., Prolonged treatment of fair-skinned mice with topical forskolin causes persistent tanning and UV protection. Pigment Cell Melanoma Res. 22 (2009), 219–229.
18. [18] de Oliveira, E., Saraiva, J., de Albuquerque, S., Marchetti, J., Solid dispersion of ursolic acid in Gelucire 50/13: a strategy to enhance drug release and trypanocidal activity. AAPS PharmSciTech 13 (2012), 1436–1445.
19. [19] Li, G., Zhang, X., You, J., Song, Y., Sun, Z., Xia, L., Suo, Y., Highly sensitive and selective pre-column derivatization high-performance liquid chromatography approach for rapid determination of triterpenes oleanolic and ursolic acids and application to Swertia species: optimization of triterpenic acids extraction and pre-column derivatization using response surface methodology. Anal. Chim. Acta 688 (2011), 208–218.
20. [20] Balanehru, S., Nagarajan, B., Protective effect of oleanolic acid and ursolic acid against lipid peroxidation. Biochem. Int. 24 (1991), 981–990.
21. [21] Ovesna, Z., Vachalkova, A., Horvathova, K., Tothova, D., Pentacyclic triterpenoic acids: new chemoprotective compounds Minireview. Neoplasma 51 (2004), 327–333.
22. [22] Raphael, T., Kuttan, G., Effect of naturally occurring triterpenoids glycyrrhizic acid ursolic acid, oleanolic acid and nomilin on the immune system. Phytomedicine 10 (2003), 483–489.
23. [23] Zhang, W., Hong, D., Zhou, Y., Zhang, Y., Shen, Q., Li, J., et al. Ursolic acid and its derivative inhibit protein tyrosine phosphatase 1B enhancing insulin receptor phosphorylation and stimulating glucose uptake. Biochim. Biophys. Acta 1760 (2006), 1505–1512.
24. [24] Chen, H., Wang, Y., Zhai, Y., Zhai, G., Wang, Z., Liu, J., Development of a ropivacaine-loaded nanostructured lipid carrier formulation for transdermal delivery. Colloids Surf. A: Physicochem. Eng. Asp. 465 (2015), 130–136.
25. [25] Joshi, M., Patravale, V., Nanostructured lipid carrier (NLC) based gel of celecoxib. Int. J. Pharm. 346 (2008), 124–132.
26. [26] Müller, R.H., Mehnert, W., Lucks, J.S., Schwarz, C., Zur Mühlen, A., Weyhers, H., Freytas, C., Rühl, D., Solid lipid nanoparticles (SLN)—an alternative colloidal carrier system for controlled drug delivery. Eur. J. Pharm. Biopharm. 41 (1995), 62–69.
27. [27] Souto, E.B., Wissing, S.A., Barbosa, C.M., Müller, R.H., Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery. Int. J. Pharm. 278 (2004), 71–77.
28. [28] Souto, E.B., Müller, R.H., SLN and NLC for topical delivery of ketoconazole. J. Microencapsul. 5 (2005), 501–510.
29. [29] Guo, T., Zhang, Y., Zhao, J., Zhu, C., Feng, N., Nanostructured lipid carriers for percutaneous administration of alkaloids isolated from Aconitum sinomontanum. J. Nanobiotechnol. 13 (2015), 1–14.
30. [30] Müller, R.H., Radtke, M., Wissing, S.A., Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54 (2002), 131–155.
31. [31] Müller, R.H., Radtke, M., Wissing, S.A., Nanostructured lipid matrices for improved microencapsulation of drugs. Int. J. Pharm. 242 (2002), 121–128.
32. [32] Tiwari, R., Pathak, K., Nanostructured lipid carrier versus solid lipid nanoparticles of simvastatin: comparative analysis of characteristics, pharmacokinetics and tissue uptake. Int. J. Pharm. 415 (2011), 232–243.
33. [33] Loo, C.H., Basri, M., Ismail, R., Lau, H., Tejo, B., Kanthimathi, M.S., Hassan, H.A., Choo, Y.M., Effect of compositions in nanostructured lipid carriers (NLC) on skin hydration and occlusion. Int. J. Nanomedicine 8 (2013), 13–22.
34. [34] Hanson, W., Theoretical concepts. Handbook of Dissolution Testing, 1982, Pharmaceutical Technology Publications.
35. [35] Okonogi, S., Riangjanapatee, P., Physicochemical characterization of lycopene-loaded nanostructured lipid carrier formulations for topical administration. Int. J. Pharm. 478 (2015), 726–735.
36. [36] Patel, D., Dasgupta, S., Dey, S., Ramani, Y.R., Ray, S., Mazumder, B., Nanostructured lipid carriers (NLC)-Based gel for the topical delivery of aceclofenac: preparation, characterization, and In vivo evaluation. Sci. Pharm. 80 (2012), 749–764.
37. [37] Yang, Y., Corona, A. III, Bhatia, S.R., Henson, M.A., The controlled aggregation and tunable viscosity of nanostructured lipid carrier dispersions. Colloids Surf. A: Physicochem. Eng. Asp. 482 (2015), 138–147.
38. [38] Bondì, M.L., Azzolina, A., Craparo, E.F., Botto, C., Amore, E., Giammona, G., Cervello, M., Entrapment of an EGFR inhibitor into nanostructured lipid carriers (NLC) improves its antitumor activity against human hepatocarcinoma cells. J. Nanobiotechnol., 12, 2014, 21, 10.1186/1477-3155-12-21.
39. [39] Grabowski, T., Gumułka, S.W., Borucka, B., Raszewski, W., Analysis relationships between pharmacokinetic parameters in silico/in vivo of selected antiviral drugs based on structural analysis. Adv. Clin. Exp. Med. 17 (2008), 285–292.